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Abstract
Objective—An association between 25-hydroxyvitamin D (25[OH]D; vitamin D) deficiency and 
increased cardiovascular (CV) risk factors and CV disease (CVD) has been shown in general 
population studies. Vitamin D deficiency has been noted in systemic lupus erythematosus (SLE), 
and CVD is a major cause of morbidity and mortality in SLE. The objectives of this study were to 
estimate the associations of 25(OH)D levels with CV risk factors and to determine whether low 
baseline 25(OH)D levels predict future CV events in patients participating in an international 
inception cohort.
Methods—Data were collected on 890 participants, including demographics, SLE activity and 
damage assessments, CV risk factors and events, medications, laboratory assessments of 25(OH)D 
levels, and inflammatory markers. Multiple logistic and Cox regressions were used to estimate the 
associations of baseline 25(OH)D levels with baseline CV risk factors and CVD events. The 
models were adjusted for age, sex, race, season, and country, with and without body mass index.
Results—Patients in the higher quartiles of 25(OH)D were less likely to have hypertension and 
hyperlipidemia and were more likely to have lower C-reactive protein levels and lower Systemic 
Lupus Erythematosus Disease Activity Index 2000 scores at baseline when compared with the first 
quartile. Vitamin D levels were not independently associated with CVD event incidence; however, 
hazard ratios for CVD event incidence decreased with successively higher quartiles.
Conclusion—Lower baseline 25(OH)D levels are associated with higher risk for CV risk factors 
and more active SLE at baseline. There may be a trend toward a lower likelihood of CVD events in 
those with higher baseline 25(OH)D levels.
INTRODUCTION
25-Hydroxyvitamin D (25[OH]D; vitamin D) deficiency has been associated with increased 
cardiovascular disease (CVD) (1–4) and CVD risk (5) in the general population. The Third 
National Health and Nutrition Examination Survey and other cross-sectional cohort studies 
found serum vitamin D levels to be inversely associated with hypertension, diabetes 
mellitus, obesity, and hypertriglyceridemia (5,6). Furthermore, there is growing evidence 
that vitamin D deficiency is associated with an increased prevalence of CVD events, 
including myocardial infarction (MI), congestive heart failure (CHF), stroke, angina, and 
peripheral arterial disease (1–4). In the Health Professionals Follow-Up Study, which 
included 18,225 men, vitamin D levels were found to be an independent risk factor for MI. 
Furthermore, men with 25(OH)D levels ≤15 ng/ml were at a significantly greater risk for MI 
than those who had sufficient 25(OH)D levels (>30 ng/ml), even after controlling for 
confounders (1). Similarly, as noted in the Third National Health and Nutrition Examination 
Survey, 1,308 men and women with self-reported CVD had a significantly greater frequency 
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(29.3% versus 21.4%; P < 0.0001) of 25(OH)D deficiency (defined as <20 ng/ml) compared 
to those without CVD (4).
Several studies have established CVD to be a major cause of morbidity and mortality in 
patients with chronic inflammatory diseases, including systemic lupus erythematosus (SLE; 
lupus) (7–10). In fact, SLE, like diabetes mellitus, is thought to be an independent risk factor 
for the development of atherosclerosis (11), and patients with SLE have been found to have 
a 5-fold increase in MI at a significantly earlier age (49 versus 69 years) (12).
Vitamin D is also thought to have a significant role in several autoimmune diseases, 
including SLE (13). The vitamin D receptor is expressed in cells involved in the innate and 
adaptive immune responses, and this receptor is thought to have immunomodulatory, 
antiproliferative, antibacterial, and antiinflammatory properties (13). Patients with SLE are 
also known to have lower levels of 25(OH)D, with measurements near or <20 ng/ml (14,15), 
and in some cases critically low at <10 ng/ml (15,16). Lower levels of vitamin D have been 
shown to correlate with increased SLE disease activity (17,18), and studies using animal 
models of SLE (19) demonstrated attenuation of some manifestations with increasing 
vitamin D intake (19,20). We previously demonstrated significant associations between 
selected CVD risk factors and 25(OH)D levels in women with SLE, although most of the 
relationships were partially explained by body mass index (BMI) (21). We extended our 
studies to further define the relationship between vitamin D and CVD events in a large 
international inception cohort of women and men with SLE.
PATIENTS AND METHODS
Systemic Lupus International Collaborating Clinics (SLICC) Registry for Atherosclerosis
At the time of this investigation, the SLICC comprised 27 centers from 11 countries in North 
America, Europe, and Asia. An inception cohort of 1,427 patients had been assembled 
according to a standardized protocol between 2000 and 2012 to study risk factors for 
atherosclerosis and cardiovascular events. Patients followed at participating centers were 
enrolled in the registry within 15 months of their date of diagnosis, based on ≥4 American 
College of Rheumatology (ACR) classification criteria for SLE (22). Demographic data as 
well as data collected on clinical factors, laboratory factors, cardiovascular events, and 
coronary artery disease risk factors were submitted to the coordinating center at the 
University of Toronto at enrollment and once annually using standardized data collection 
forms. Disease activity was measured by the Systemic Lupus Erythematosus Disease 
Activity Index 2000 (SLEDAI-2K) (23). Damage was measured by the SLICC/ACR 
Damage Index (24). Laboratory tests necessary to evaluate disease activity and complete 
disease activity and damage measures were performed locally. Low complement levels were 
defined as a decrease in CH50, C3, or C4 below the lower limit of normal for the testing 
laboratory. Double-stranded DNA testing was done locally, with abnormal values defined by 
the local laboratory parameters. Low-density lipoprotein (LDL) cholesterol, homocysteine 
levels, and C-reactive protein (CRP) levels were measured in a subset of patients at 
enrollment. Although the majority of homocysteine levels were measured by a central 
laboratory, CRP levels were measured in local laboratories. Lupus anticoagulant and IgG 
anticardiolipin antibody testing was performed at the Oklahoma Medical Research 
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Foundation. The study has been approved by the research ethics boards of all participating 
institutions.
Vitamin D measurement
Of the 1,427 patients, 890 had blood samples available for vitamin D testing. After 
excluding 13 subjects due to pregnancy and 2 subjects with CVD events prior to baseline, 
875 subjects were included in our analyses. 25(OH)D was performed by DiaSorin in Toronto 
through the University Health Network Laboratory Medicine Program. The intraassay 
coefficient of variation was 10.8% and the interassay coefficient of variation was 9.4%.
Traditional CVD risk factors
Traditional CVD risk factors included hypertension, BMI, hypercholesterolemia, smoking, 
diabetes mellitus, and postmenopause status. Hypertension was defined as a systolic blood 
pressure ≥140 mm Hg, a diastolic blood pressure ≥90 mm Hg, or taking current treatment 
for hypertension. Hyperlipidemia was defined as present if LDL cholesterol was ≥130 mg/dl 
or if the patient was currently receiving lipid-lowering medications. Diabetes mellitus was 
defined as present if fasting plasma glucose was ≥126 mg/dl or if currently taking 
medication for diabetes mellitus. Postmenopause status was defined as the absence of 
menses for 12 months or bilateral oophorectomy. Self-reported alcohol consumption and 
hours spent in sedentary, slight, moderate, or heavy physical activity on an average day were 
also collected.
CVD events
Information about incident CVD events, including MI, angina, CHF, peripheral vascular 
disease, transient ischemic attacks, or strokes (cardiovascular accident), based on definitions 
previously described, was collected (25). The type and date of event were recorded over the 
course of 11 years, between 2000 and 2011. Only the first CVD event for each patient was 
included in the analysis.
Statistical analysis
Means, SDs, percentiles, and ranges were used to describe measured patient characteristics 
and laboratory values. Multiple linear and logistic regressions were used to investigate 
associations of baseline 25(OH)D levels by quartiles with each cardiovascular risk factor at 
baseline, with the first quartile (Q1) as the reference quartile. Linear regression was used for 
continuous cardiovascular risk factors and logistic regression was used for dichotomous 
cardiovascular risk factors. The multivariate analyses were further adjusted for age, season 
(26), white race, country (Korea, UK, US, or other), sex, and BMI. To adjust for season, the 
lower ultraviolet light season (winter) was defined as having vitamin D levels drawn 
between October and March, and the higher ultraviolet light season (summer) was defined as 
having vitamin D levels drawn between April and September (26). Cox proportional hazards 
models were used to describe the risk of CVD event incidence over time, with Q1 as the 
reference quartile.
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RESULTS
25(OH)D baseline levels were measured in 875 patients (53.6% white, 16.7% African 
American, 3.1% Hispanic, 22.5% Asian, and 4.6% other) at the time of enrollment. The 
majority (89.8%) were women, 13% of whom were postmenopausal. Patients were 
geographically located in Canada (29.4%), the US (26.6%), the UK (22.5%), Korea (15.8%), 
Sweden (3%), Spain (0.7%), and Switzerland (0.3%). Forty-two percent of subjects were 
married and subjects had a mean ± SD of 14 ± 3.2 years of education, including secondary 
and college education. Seventy-two percent of subjects had 25(OH)D levels <30 ng/ml and 
27.7% of subjects had 25(OH)D levels ≥30 ng/ml. The mean ± SD 25(OH)D level was 23.8 
± 13.4 ng/ml (Table 1). The first quartile (Q1) of 25(OH)D consisted of levels 4–13 ng/ml, 
the second quartile (Q2) of 14–21 ng/ml, the third quartile (Q3) of 22–30 ng/ml, and the 
fourth quartile (Q4) of 31–91 ng/ml.
Approximately 32% of subjects consumed alcohol on an average day, with mean ± SD 
consumption of 1.17 ± 3.44 units daily. Those in the higher 25(OH)D quartiles were more 
likely to consume alcohol on an average day (P = 0.004 by analysis of variance [ANOVA]; 
data not shown); however, it should be noted that the number of persons consuming alcohol 
was small.
Participants spent more time in an average day in sedentary activity (mean ± SD 7.02 ± 3.96 
hours) than in heavy activity (mean ± SD 0.49 ± 1.31 hours). Time spent in various activity 
levels did not differ between 25(OH)D quartiles, nor was it related to 25(OH)D level (data 
not shown).
The mean ± SD age and disease duration at enrollment were 39.3 ± 13.5 years and 0.5 ± 0.4 
years, respectively. The mean ± SD SLEDAI-2K score was 5.6 ± 5.5; lower quartiles 
exhibited higher mean SLEDAI-2K scores (P < 0.001 by ANOVA), with a mean 
SLEDAI-2K score of 7.0 in Q1 and 4.7 in Q4. One-hundred fifty-seven patients (20.3%) 
were positive for lupus anticoagulant and 8.8% were positive for IgM or IgG anticardiolipin 
antibodies at moderate to high levels (≥14.1–50 IgM phospholipid/IgG phospholipid units, 
respectively) (Table 2).
At baseline, corticosteroids were used in 67.4% (mean ± SD daily dose 23.3 ± 15.9 mg), 
hydroxychloroquine in 66.4%, and immunosuppressants (including azathioprine, 
cyclophosphamide, methotrexate, cyclosporine, and mycophenolate mofetil) in 37.8% of 
patients. Cohort members in the lower 25(OH)D quartiles were more likely to be taking a 
corticosteroid at baseline (P < 0.001 by ANOVA; data not shown); of the 219 patients in Q1, 
174 (79.5%) were taking a corticosteroid at baseline, and of the 216 patients in Q4, 125 
(57.9%) were taking a corticosteroid. However, the mean daily corticosteroid dose did not 
differ between quartiles (P = 0.70 by ANOVA; data not shown). Those in the lower 
25(OH)D quartiles were also less likely to be taking an antimalarial at baseline (P < 0.001 
by ANOVA; data not shown). Those in our lower 25(OH)D quartiles were also less likely to 
be taking an antimalarial medication at baseline (P < 0.001 by ANOVA; data not shown). Of 
the 219 patients in Q1, 124 (56.7%) were taking an antimalarial, and of the 216 patients in 
Q4, 155 (71.7%) were taking an antimalarial. Of the women, 7.7% had used hormone 
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replacement therapy and 49.3% had used oral contraceptives. Although 25.3% reported 
taking vitamin D supplements, the mean dose was not known. Bisphosphonate use at 
baseline was present in 8.7% of patients.
Hypertension was present in 34.5%, hyperlipidemia in 15.7%, diabetes mellitus in 6.5%, and 
current smoking in 15.4% of patients at baseline (Table 3). Mean ± SD objective 
cardiovascular risk factor measurements included systolic blood pressure of 119.9 ± 17.3 
mm Hg, diastolic blood pressure of 74.9 ± 11.2 mm Hg, BMI of 25.1 ± 5.9 kg/m2, fasting 
glucose of 91.6 ± 31.9, total cholesterol of 189.3 ± 57.1 mg/dl (with LDL cholesterol of 
106.6 ± 45.4 mg/dl), creatinine of 0.86 ± 0.79 mg/dl, and CRP level of 0.8 ± 1.7 mg/dl 
(Table 2). Eighty-four percent of patients had normal CRP levels (<1.0 mg/dl). Renal 
disease, as defined by the ACR revised classification criteria, was present in 26.2% at 
baseline (22).
In the unadjusted model for the associations of 25(OH)D levels with cardiovascular risk 
factors (Tables 4 and 5), lower 25(OH)D levels were significantly associated with the 
presence of hypertension, the presence of hyperlipidemia, higher CRP levels, and higher 
SLEDAI-2K scores. After adjustment for age, season, white race, country (Korea, UK, US, 
or other), and sex, these associations remained significant. Further correcting for BMI did 
not abrogate these associations. 25(OH)D levels were not associated with the presence of 
diabetes mellitus. Post hoc adjustment with glucocorticoid and antimalarial use did not 
affect the relationship between SLEDAI-2K and 25(OH)D (data not shown).
Of the 875 subjects, 36 had reported incident CVD events after enrollment. Only 1 CVD 
event was fatal. Mean ± SD followup time was 5.72 ± 3.03 years. Three subjects were 
excluded because of events attributed to postpartum cardiomyopathy, overhydration, and 
shrinking lung syndrome. An additional subject was excluded due to an unknown event date, 
which led to a final 32 subjects for analysis. Seven subjects reported MI, 6 reported angina, 
4 reported peripheral vascular disease, 4 reported CHF, 7 reported transient ischemic attacks, 
and 4 reported cerebrovascular accident. Mean ± SD time to an event was 3.13 ± 2.19 years. 
Of the 32 subjects, 9 were in 25(OH)D Q1, 13 were in 25(OH)D Q2, 5 were in 25(OH)D 
Q3, and 5 were in 25(OH)D Q4 at baseline. A statistically significant association was not 
demonstrated between 25(OH)D levels and risk for CVD events (Table 6). However, a trend 
was present that suggests those in higher quartiles are less likely (lower hazard ratios) to 
develop any CVD event when compared with the lowest quartile. Of the 32 subjects with 
incident events, 25 were taking corticosteroids. However, adjusting for current use of an 
antimalarial or current use of a corticosteroid did not affect the Cox model results (data not 
shown).
DISCUSSION
We have investigated the relationship of baseline serum 25(OH)D levels with baseline 
cardiovascular risk factors and risk for future cardiovascular events. To our knowledge, this 
is the first investigation of risk for future cardiovascular events in a large international cohort 
of SLE patients. We have found that lower 25(OH)D levels are independently associated 
with the presence of hypertension, hyperlipidemia, and increased CRP levels after 
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controlling for age, season, sex, race, country, and BMI. We have also found that those with 
lower 25(OH)D levels exhibit a trend toward increased risk for future cardiovascular events.
In concordance with previous studies (27–32), we found that the mean 25(OH)D level was 
low, with 72.3% being <30 ng/ml. In our cohort, those in the lower 25(OH)D quartiles were 
more likely to have hypertension and hyperlipidemia compared with the highest quartile, 
even after controlling for age, season, sex, race, country/location, and BMI. Similar findings 
have been repeatedly noted in the general population (5,33,34) and are thought to be related 
to the effects of vitamin D on the renin–angiotensin system. Studies have demonstrated 
elevated renin levels in vitamin D deficiency in both animal and human models (35,36).
The explanation for the association of lower 25(OH)D levels and higher CRP levels is not as 
clear; controlling for BMI did not affect this relationship significantly. In the general 
population, studies have reported inconsistent findings with regard to CRP. Hyppönen et al 
reported an association between 25(OH)D levels and preclinical variations in CRP levels 
even when controlling for age, month, and sex, but this relationship did not persist after 
adjusting for lifestyle factors and adiposity (6). Shea et al, however, noted no association 
between 25(OH)D and CRP, and even after vitamin D supplementation, found no significant 
change in CRP level per 2-fold increase in 25(OH)D level (37). In our previous study of SLE 
patients, CRP was not associated with 25(OH)D, but the CRP level in that population was 
higher than in this international inception cohort (mean ± SD 4.2 ± 10.2 versus 0.8 ± 1.7 
mg/dl) (21). While CRP level often increases with age (the mean age in this cohort was 39.3 
years versus 43.2 years in our previous study), in the general population, CRP level is 
thought to double from ~1 mg/dl in ages 25–34 years to ~2 mg/dl in ages 55–64 years, 
suggesting that age alone cannot account for the increase in CRP level. The mean 25(OH)D 
level in our previous study was 27.1 ng/ml compared with 23.8 ng/ml, and some studies 
have suggested that an inverse relationship between CRP and 25(OH)D exists only in 
25(OH)D levels <21 ng/ml and that CRP levels may actually increase with 25(OH)D levels 
≥21 ng/ml in the general population (38). Akin et al also reported an inverse association 
between 25(OH)D and CRP only in those with deficient 25(OH)D levels <20 ng/ml (34), 
and it may be that the 25(OH)D levels in this cohort were low enough to show an 
association.
We found the higher 25(OH)D quartiles to be more likely to have lower SLEDAI-2K scores 
when compared with the lowest quartile, even after controlling for cardiovascular risk 
factors. This is consistent with several recent studies (28,30,31,39,40). Of interest, in a study 
of Thai SLE patients, Sumethkul et al found that 25(OH)D levels were inversely correlated 
with the SLEDAI-2K, but not with the adjusted SLEDAI-2K (excluding nephritis variables), 
which suggested that lupus nephritis is a major predictor of low 25(OH)D (32). Ruiz-
Irastorza et al did not find a correlation between 25(OH)D and SLEDAI scores, but 53% of 
their population had a SLEDAI score of 0, 28% had a SLEDAI score of 1–3, and 19% had a 
SLEDAI score of >3 (27), whereas our population had much higher disease activity at 
baseline, with 18.2% with a SLEDAI-2K score of 0, 18.7% with a SLEDAI-2K score of 1–3, 
and 62.0% with a SLEDAI-2K score of >3. Some have found that those with SLEDAI scores 
>3 had the lowest 25(OH)D levels (28), and it may be that the association is more apparent 
given the more active disease in our population.
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Participants in the lower 25(OH)D quartiles were more likely to be taking a corticosteroid at 
baseline and had higher mean SLEDAI-2K scores. Higher prevalence of current 
corticosteroid use could reflect the higher amount of disease activity, and concurrently, the 
mean corticosteroid dose in our cohort was >23 mg daily, which is significantly higher than 
most other studies. Glucocorticoid use has been documented to be associated with lower 
25(OH)D levels (41) and is thought to be related to an increase in 24α-hydroxylase activity 
(42). It is not known if this is a dose-dependent relationship; however, the mean daily 
corticosteroid dose did not differ between quartiles.
Evidence regarding a relationship between antimalarial use and 25(OH)D levels is 
inconclusive. Hydroxychloroquine has been suspected to inhibit the conversion of 25(OH)D 
to its biologically more active form 1,25-dihydroxyvitamin D (43), and as such, Ruiz-
Irastorza et al reported that hydroxychloroquine was associated with higher 25(OH)D levels 
(27). However, Huisman et al (14) and Toloza et al (29) et al did not find any association 
between 25(OH)D levels and antimalarial use.
Although both glucocorticoids and antimalarials have been shown to independently affect 
25(OH)D levels and in our case may be related to disease activity/SLEDAI-2K scores, 
adjusting for each did not affect the relationship between SLEDAI-2K and 25(OH)D. Of 
note, 43% (n = 377) were taking both an antimalarial and a corticosteroid.
We did not find a statistically significant relationship between baseline 25(OH)D level and 
risk for cardiovascular event occurrence over the 11-year followup; however, those in the 
higher 25(OH)D quartiles (Q3 and Q4) were less likely to develop an incident 
cardiovascular event when compared to those in Q1. Those in Q2 had more cardiovascular 
events when compared with the other quartiles, but the reason for this observation remains to 
be determined.
In non-SLE populations, there are reports of low 25(OH)D levels in association with 
cardiovascular events (1–3,33,34). This has prompted investigation into a relationship 
between 25(OH)D levels and subclinical atherosclerosis. Low levels of 25(OH)D also have 
been shown to be associated with incident coronary artery calcium (CAC) in the Multi-
Ethnic Study of Atherosclerosis (44). In SLE populations, Reynolds et al reported that lower 
25(OH)D levels were associated with an increase in arterial pulse wave velocity that 
persisted, although slightly attenuated, even after adjusting for SLEDAI-2K score (31). Our 
previous study did not find a relationship between 25(OH)D and carotid intima-media 
thickness (CIMT), carotid plaque, CAC, and aorta calcium, before or after adjusting for age, 
season, and race. Similarly, Reynolds et al did not find a relationship between 25(OH)D and 
CIMT or plaque (31). Ravenell et al, however, did find that 25(OH)D levels were lower in 
those with higher total plaque areas (45). Such findings suggest that low 25(OH)D levels 
may infer a greater risk for CVD and events in SLE populations, and that the lower levels of 
25(OH)D seen in SLE populations when compared with the general population may be a 
contributing factor to the early cardiovascular morbidity and mortality seen in SLE patients.
Those cohort members in the higher 25 (OH)D quartiles were more likely to be taking an 
antimalarial medication, and it has been reported that ever use of hydroxychloroquine is 
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protective against CAC (46), which may have contributed to the decreased risk for a 
cardiovascular event in the higher quartiles. Of the 32 subjects with incident events, 15 were 
taking an antimalarial medication and 16 were not. Data on whether or not corticosteroids 
contribute to atherosclerosis are controversial, but some studies suggest that treating 
inflammation may decrease the progression of subclinical atherosclerosis. For example, one 
study followed serial carotid ultrasounds and found that progression of subclinical 
atherosclerosis was associated with lower mean doses of corticosteroids and less aggressive 
immunosuppressive therapy (47). However, we did not find that adjusting for antimalarial 
use or current corticosteroid use affected the Cox model results.
Given these findings, the question remains whether supplementation with vitamin D should 
be more aggressively pursued in the management of SLE. Abou-Raya et al reported 
improvement in SLEDAI scores after 12 months of 2,000 IU daily oral cholecalciferol when 
compared with placebo, despite noting that 1 of 3 in the intervention group did not reach 
optimal 25(OH)D levels (40). Petri et al gave 50,000 IU of vitamin D2 and calcium/D3 200 
IU twice daily to patients with 25(OH)D levels <40 ng/ml over a period of approximately 
2.5 years. They reported that a 20-IU increase in 25(OH)D level resulted in a 21% decrease 
in the odds of having a Safety of Estrogens in Lupus Erythematosus National Assessment–
SLEDAI score ≥5 (48). While these reports suggest that supplementation may be beneficial 
in reducing disease activity, interventional studies investigating incident cardiovascular event 
risk would be useful, since literature in the general population has not supported the utility 
of supplementation for cardiovascular risk reduction. In the Women’s Health Initiative 
(WHI) study, Hsia et al reported no effect on coronary or cerebrovascular risk in 36,282 
postmenopausal women over 7 years of calcium/vitamin D supplementation, although they 
acknowledged that it was possible the supplementation dose was not high enough (49). 
Another study through the WHI noted that CAC scores were not significantly worse in those 
taking moderate dosages (1,000 mg/day) of calcium and vitamin D (400 IU/day) (50).
We recognize that our study has several limitations that should be taken into consideration 
when evaluating our results. Our results suggest an association between low 25(OH)D levels 
and higher risk for certain cardiovascular risk factors; however, causality cannot be implied. 
Low 25(OH)D may be a marker of overall poor health, as evidenced by physical inactivity 
with lack of sunshine, rather than itself a cause of CVD. The number of incident 
cardiovascular events was small and we did not control for renal disease, which may have 
affected both vitamin D levels and CVD risk factors. However, only 26.2% fulfilled the ACR 
criteria for renal disease at enrollment. In addition, we did not control for estrogen use, nor 
did we specifically control for antimalarial or corticosteroid use. However, the post hoc 
exploratory analyses described earlier did not change the Cox model results.
This study supports an association between lower 25(OH)D levels and certain cardiovascular 
risk factors. We have also reported a possible association between lower 25(OH)D levels and 
increased risk for a future cardiovascular event. Specific attention to maintaining optimal 
25(OH)D levels may be beneficial in the management of SLE.
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Significance & Innovations
• Systemic lupus erythematosus (SLE) patients with higher 25-hydroxyvitamin D 
(25[OH]D) levels are more likely to have lower SLE disease activity.
• SLE patients with higher 25(OH)D levels are less likely to have hypertension 
and hyperlipidemia.
• An association may exist between higher baseline 25(OH)D levels and lower 
risk for future cardiovascular disease events.
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Table 1
Demographics of the Systemic Lupus International Collaborating Clinics Registry for Atherosclerosis cohort 
at enrollment*
All (n = 875) Women (n = 786) Men (n = 89)
Age, mean ± SD years 39.3 ± 13.5 38.9 ± 13.1 42.9 ± 16.4
Women, % 89.8
Ethnicity, %
 White 53.6 52.5 62.9
 African American 16.7 16.8 11.2
 Hispanic 3.1 3.2 2.2
 Asian 22.5 22.5 22.5
 Other 4.6 5.0 1.1
Country, %
 Canada 29.4 28.2 32.6
 Iceland 2.4 2.5 1.1
 Korea 15.8 15.8 15.7
 Spain 0.7 0.8 0
 Sweden 3.0 2.9 3.4
 Switzerland 0.3 0.3 1.1
 UK 22.5 23.0 18.0
 US 26.6 26.5 28.1
Married, % 41.9 41.3 47.2
Education, mean ± SD years 14.0 ± 3.2 14.0 ± 3.2 13.2 ± 3.2
Vitamin D levels
 25(OH)D, mean ± SD ng/ml 23.8 ± 13.4 23.8 ± 13.6 23.7 ± 11.6
 25(OH)D <30 ng/ml, % 72.3 71.6 78.7
 25(OH)D ≥30 ng/ml, % 27.7 28.4 21.3
Lifestyle factors
 Daily alcohol use, % (n) 32.0 (862) 30.3 (775) 30.3 (87)
  Amount, mean ± SD units 1.17 ± 3.44 0.92 ± 2.23 3.41 ± 8.23
 Sedentary activity, mean ± SD hours/week 7.02 ± 3.96 6.92 ± 3.94 7.98 ± 4.03
 Slight activity, mean ± SD hours/week 5.23 ± 3.15 5.33 ± 3.14 4.34 ± 3.09
 Moderate activity, mean ± SD hours/week 2.48 ± 2.91 2.52 ± 2.91 2.14 ± 2.84
 Heavy activity, mean ± SD hours/week 0.49 ± 1.31 0.48 ± 1.3 0.60 ± 1.39
Cardiovascular medications
 Hyperlipidemia therapy, %
  Current 9.0 8.9 10.1
  Past 1.9 2.0 1.1
 Aspirin, % 14.2 13.9 16.9
 Antihypertensive medications, %
  Current 10.2 24.4 39.3
  Past 25.9 10.1 11.2
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All (n = 875) Women (n = 786) Men (n = 89)
SLE-related factors
 Disease duration, mean ± SD years 0.5 ± 0.4 0.4 ± 0.3 0.5 ± 0.3
 Taking corticosteroids, %
  Current 67.4 66.4 82.0
  Never 24.2 25.0 14.6
 Current corticosteroid dose, mean ± SD mg 23.3 ± 15.9 23.1 ± 16.1 25.0 ± 14.5
 Taking antimalarials, % 66.4 67.0 60.7
 Taking immunosuppressants, %
  Current 37.8 36.1 52.8
  Never 59.3 60.8 46.1
 Renal disease, % 26.2 25.2 34.8
 SLEDAI-2K score, mean ± SD (n) 5.6 ± 5.5 5.6 ± 5.5 (783) 6.0 ± 5.2 (89)
 Low complement, % (n)† 42.1 42.0 (709) 42.7 (82)
 Positive dsDNA, % (n)‡ 41.8 41.2 (701) 46.3 (82)
Bone medications
 Estrogen use ever, % (n)
  HRT 7.7 (779)
  OCPs 49.3 (781)
 Calcium, % 32.2 32.4 30.3
 Vitamin D, % 25.3 25.3 24.7
 Bisphosphonates, % 8.7 8.1 13.4
*25(OH)D = 25-hydroxyvitamin D; SLE = systemic lupus erythematosus; SLEDAI-2K = Systemic Lupus Erythematosus Disease Activity Index 
2000; dsDNA = double-stranded DNA; HRT = hormone replacement therapy; OCPs = oral contraceptives.
†
Defined as a decrease in CH50, C3, or C4 below the lower limit of normal for the testing laboratory.
‡
Increased DNA binding above the normal range based on local testing laboratory parameters.
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Table 2
Objective and laboratory measures of the Systemic Lupus International Collaborating Clinics Registry for 
Atherosclerosis cohort at enrollment*
All Women (n = 786) Men (n = 89)
Cardiovascular risk factor Value N Value N Value N
Systolic blood pressure, mm Hg 119.9 ± 17.3 864 119.0 ± 17.0 775 127.9 ± 17.9
Diastolic blood pressure, mm Hg 74.9 ± 11.2 585 74.6 ± 11.0 769 77.6 ± 11.9
Body mass index, kg/m2 25.1 ± 5.9 845 25.1 ± 6.0 762 25.4 ± 4.7 85
Fasting glucose, mg/dl 91.6 ± 31.9 733 91.3 ± 32.9 659 94.2 ± 20.6 74
Total cholesterol, mg/dl 189.3 ± 57.1 776 189.7 ± 57.7 697 185.7 ± 52.3 79
HDL cholesterol, mg/dl 55.2 ± 26.7 408 55.5 ± 26.6 370 52.7 ± 28.5 38
LDL cholesterol, mg/dl 106.6 ± 45.4 336 106.2 ± 46.1 304 110.7 ± 39.0 32
Triglycerides, mg/dl 136.4 ± 85.7 755 132.7 ± 82.4 680 169.2 ± 106.1 75
Lipoprotein(a), mg/dl 36.5 ± 40.7 17 40.0 ± 44.23 14 20.1 ± 7.2 3
Fibrinogen, mg/dl 436.4 ± 126.0 11 407.12 ± 133.5 8 514.3 ± 67.3 3
C-reactive protein, mg/dl 0.8 ± 1.7 655 0.76 ± 1.7 587 0.65 ± 1.2 68
Homocysteine, μmoles/liter 12.9 ± 43.5 489 13.3 ± 45.9 436 11.8 ± 3.7 53
Lupus anticoagulant, % 20.3 772 19.0 691 32.1 81
Moderate/high aCL positive, %† 8.8 729 8.7 652 9.1 77
Creatinine, mg/dl‡ 0.86 ± 0.79 436 0.85 ± 0.82 402 0.97 ± 0.17 34
*Values are the mean ± SD unless indicated otherwise. HDL = high-density lipoprotein; LDL = low-density lipoprotein; aCL = anticardiolipin 
antibody.
†
Defined as ≥14.1–50 IgM phospholipid/IgG phospholipid units.
‡
Three outliers removed (creatinine >15 mg/dl).
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Table 3
Percentage of subjects with cardiovascular risk factors at enrollment
%
Hypertension (n = 301/873) 34.5
 Women (n = 251/786) 31.9
 Men (n = 50/89) 56.2
Hyperlipidemia (n = 137/875) 15.7
 Women (n = 121/786) 15.4
 Men (n = 16/89) 18.0
Diabetes mellitus (n = 56/861) 6.5
 Women (n = 50/786) 6.4
 Men (n = 6/89) 6.7
Current smoker (n = 135/875) 15.4
 Women (n = 115/785) 14.6
 Men (n = 20/89) 22.5
Ex-smoker (n = 181/875) 20.7
 Women (n = 157/784) 20.0
 Men (n = 24/89) 27.0
Never smoker (n = 559/875) 63.9
 Women (n = 514/786) 65.4
 Men (n = 45/89) 50.6
Postmenopausal (n = 102/786) 13.0
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Table 4
25(OH)D quartiles and binary CV risk factors at enrollment*
Unadjusted model Adjusted model 1† Adjusted model 2‡
CV risk factor OR 95% CI OR 95% CI OR 95% CI
Hypertension
 Q2 0.84 0.58, 1.24 0.81 0.55, 1.21 0.83 0.55, 1.25
 Q3 0.60§ 0.41, 0.89§ 0.66 0.43, 1.00 0.69 0.44, 1.06
 Q4 0.43§ 0.29, 0.65§ 0.44§ 0.28, 0.68§ 0.49§ 0.31, 0.77§
Diabetes mellitus
 Q2 1.14 0.56, 2.31 0.98 0.47, 2.03 0.93 0.43, 1.99
 Q3 0.54 0.22, 1.22 0.52 0.21, 1.21 0.57 0.22, 1.35
 Q4 0.81 0.37, 1.73 0.66 0.29, 1.45 0.71 0.31, 1.63
Hyperlipidemia
 Q2 0.87 0.55, 1.38 0.76 0.47, 1.22 0.80 0.49, 1.29
 Q3 0.31§ 0.17, 0.54§ 0.28§ 0.15, 0.51§ 0.30§ 0.16, 0.55§
 Q4 0.48§ 0.28, 0.79§ 0.43§ 0.24, 0.74§ 0.50§ 0.28, 0.87§
*25(OH)D = 25-hydroxyvitamin D; CV = cardiovascular; OR = odds ratio; 95% CI = 95% confidence interval; Q = 25(OH)D quartile.
†Adjusted model 1: controlled for age, season, white race, sex, and country (Korea, UK, US, or other), except for diabetes mellitus, which controls 
for age, white race, sex, and season only.
‡Adjusted model 2: controlled for same as model 1 plus body mass index.
§Statistically significant.
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Table 5
25(OH)D quartiles and continuous CV risk factors at enrollment*
Unadjusted model Adjusted model 1† Adjusted model 2‡
CV risk factor β § 95% CI β § 95% CI β § 95% CI
CRP
 Q2 −0.12 −0.48, 0.24 −0.11 −0.47, 0.25 −0.10 −0.47, 0.26
 Q3 −0.30 −0.66, 0.06 −0.30 −0.68, 0.08 −0.30 −0.69, 0.08
 Q4
−0.38¶ −0.76, −0.01¶ −0.44¶ −0.84, −0.04¶ −0.44¶ −0.85, −0.03¶
Homocysteine
 Q2 0.10 −0.04, 0.25 0.077 −0.07, 0.23 0.08 −0.08, 0.23
 Q3 −0.02 −0.16, 0.13 −0.04 −0.20, 0.12 −0.03 −0.20, 0.13
 Q4 −0.01 −0.16, 0.14 −0.04 −0.21, 0.12 −0.03 −0.21, 0.14
Creatinine
 Q2 0.14 −0.09, 0.38 0.12 −0.12, 0.36 0.13 −0.11, 0.37
 Q3 0.13 −0.10, 0.36 0.09 −0.15, 0.32 0.10 −0.15, 0.34
 Q4 0.06 −0.16, 0.28 0.02 −0.22, 0.25 0.03 −0.21, 0.27
SLEDAI-2K
 Q2
−1.22¶ −2.24, −0.20¶ −1.44¶ −2.43, −0.46¶ −1.38¶ −2.37, −0.38¶
 Q3
−1.88¶ −2.90, −0.86¶ −2.15¶ −3.17, −1.12¶ −2.16¶ −3.19, −1.12¶
 Q4
−2.27¶ −3.30, −1.25¶ −2.22¶ −3.26, −1.18¶ −2.37¶ −3.25, −1.31¶
*25(OH)D = 25-hydroxyvitamin D; CV = cardiovascular; 95% CI = 95% confidence interval; CRP = C-reactive protein; Q = 25(OH)D quartile; 
SLEDAI-2K = Systemic Lupus Erythematosus Disease Activity Index 2000.
†Adjusted model 1: controlled for age, sex, season, white race, and country (Korea, UK, US, or other).
‡Adjusted model 2: controlled for same as model 1 plus body mass index. When looking at women and men, model controlled for only age, season, 
white race, and country.
§
Represents the mean difference in risk factor between Q1 and Q2, Q3, and Q4.
¶Statistically significant.
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Table 6
25-Hydroxyvitamin D quartiles (Q) and cardiovascular disease events at followup*
No. of events HR 95% CI
Q2 13 1.15 0.46, 2.84
Q3 5 0.68 0.21, 2.13
Q4 5 0.63 0.20, 1.97
*Q1 is the referent quartile, with 9 events. HR = hazard ratio; 95% CI = 95% confidence interval.
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